Superworth

Puma Biotechnology price to book ratio PBYI

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
4.1×
10-year median
9.1×
Against its 10-year history
28th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.5× to 53.1×
Peer median
2.3×

Puma Biotechnology's price to book ratio is 4.1× as of Oct 23, 2026.

That is below its ten-year median of 9.1×, lower than on 72% of days in the last ten years.

Over that time it ranged from 1.5× in May 2025 to 53.1× in May 2020.

The median for 10 large drugmakers of a similar size is 2.3×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.1×2.2×4.1×
20252.7×1.5×2.8×
20242.1×1.7×8.7×
20235.3×3.4×9.9×
20228.7×5.1×20.3×
20217.1×7.1×27.9×
202014.2×14.2×53.1×
201919.6×8.0×44.0×
201817.5×16.8×52.9×
201746.9×5.4×50.3×
201612.4×3.7×20.4×
201510.4×9.0×65.0×
201440.6×8.7×48.8×
201331.4×6.8×106×
201259.8×4.8×65.6×

Against its peers

Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.

CompanyPrice to book ratio
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
ARVNArvinas0.8×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
PCRXPacira BioSciences2.2×
ANABAnaptysbio138×
Peer median2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Puma Biotechnology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.